Trial Profile
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Bizaxofusp (Primary) ; Bizaxofusp (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 24 Apr 2024 According to a Medicenna Therapeutics media release, data from this study will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from May 31 -June 4, 2024
- 14 Feb 2024 According to a Medicenna Therapeutics media release, the company plans to seek to apply for Breakthrough Therapy Designation (BTD) for bizaxofusp based on compelling data from this trial presented at the SNO.
- 17 Nov 2023 Results presented in the Medicenna Therapeutics media release.